ONWARD Medical Exceeds One Million Euros in Quarterly Revenue

Financial Milestone Achieved

ONWARD Medical reported that its quarterly revenues exceeded one million euros for the first time in the third quarter of 2025. Although the press release does not provide complete financial results, this announcement marks a significant milestone in the company's commercial performance. ONWARD Medical develops spinal cord stimulation technologies to assist individuals with spinal injuries and other motor disabilities. During this quarter, the company sold 40 ARC-EX® systems, thereby strengthening its position in the neurotechnology market.

Regulatory Milestones Reached

ONWARD Medical achieved several regulatory milestones during the third quarter. The company received CE certification for its ARC-EX system, which is designed to enhance hand strength and sensation following a spinal cord injury. In the United States, the company obtained an Investigational Device Exemption (IDE) from the FDA for its ARC-IM system, enabling the launch of the Empower BP study. This global and pivotal study aims to assess the safety and efficacy of this implanted neuromodulation platform, particularly for issues of blood pressure instability following a spinal injury.

Strengthening Scientific and Technological Leadership

ONWARD Medical continues to strengthen its scientific and technological leadership, as demonstrated by the simultaneous publication of two papers in the journals Nature and Nature Medicine. These highlight advancements in regulating blood pressure following a spinal cord injury, supporting the upcoming initiation of the Empower BP study. Currently, over 50 clinics in the United States are equipped with the ARC-EX system, showcasing the growing adoption of these solutions. Dave Marver, CEO of the company, mentioned that more comprehensive updates on the year's achievements will be shared during the scheduled quarterly call on November 11, 2025.